ROS1 Kinase Inhibitors for Molecular-Targeted Therapies

Area of Science:

• Oncology
• Molecular Biology
• Medicinal Chemistry

Background:

• ROS1 (receptor tyrosine kinase) regulates critical cellular functions like apoptosis and proliferation.
• ROS1 rearrangements are implicated in diverse malignancies, including non-small cell lung cancer, glioblastoma, and ovarian cancer, making it a significant drug discovery target.
• ALK kinase inhibitors demonstrate in vitro activity against ROS1 due to sequence homology, highlighting a therapeutic avenue.

Purpose of the Study:

• To review current knowledge on scaffolds targeting ROS1 rearrangements.
• To discuss synthesis methods for potential ROS1 inhibitors.
• To present biological data on potent compounds modulating ROS1 activity.

Main Methods:

• Literature review of studies on ROS1 inhibitors.
• Analysis of chemical scaffolds targeting ROS1.
• Summary of synthesis strategies and biological data for ROS1-targeting compounds.

Main Results:

• Identified various chemical scaffolds with inhibitory activity against ROS1.
• Detailed synthesis approaches for generating ROS1 inhibitors.
• Highlighted potent compounds and their biological profiles.

Conclusions:

• Despite advancements, selective and potent ROS1 inhibitors are needed for therapeutic applications.
• Medicinal chemistry efforts are vital for developing novel ROS1-targeting drugs.
• Targeting ROS1 rearrangements represents a promising strategy for treating multiple human cancers.